Preliminary data from a phase 1b extension study (NCT05292911) involving 64 individuals with MRI-PDFF 10% and BMI 28 kg/m 2 demonstrated that 50%, 44%, and 60% of participants presenting baseline alanine aminotransferase (ALT) 30 IU/L reached combined MRI-PDFF reduction 30% and ALT reduction 17 IU/L at pemvidutide doses of 1.2, 1.8, and 2.4 mg, respectively, vs
She says the biggest benefits will be for patients who need to lose a significant amount of weight between 50 and 100 pounds as well as those with Type 2 diabetes and patients with fatty liver disease
For the cortisol-perimenopause piece specifically, our tirzepatide hub covers why GIP+GLP-1 dual receptor activation maps to that biology.
Evaluation of glutathione reductase activity in colon tissue of patients with irritable bowel syndrome
However, this is uncommon and not something weve personally seen with our own supplementation or our patients use of glutathione